Regimen Improves PFS in Highly Mutated Metastatic Colorectal Cancer

By News Health
1 hour Ago

(MedPage Today) — SAN FRANCISCO — Adding modified FOLFOX6 (oxaliplatin, leucovorin, and fluorouracil) and bevacizumab (Avastin) to atezolizumab (Tecentriq) significantly improved progression-free survival (PFS) in patients with previously untreated…

Source link : https://www.medpagetoday.com/meetingcoverage/mgics/119392

Author :

Publish date : 2026-01-12 21:39:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

How Often Do Physicians Encounter 'Difficult' Patients?

Multiple Sclerosis Risk May Start Before Birth

CAR-Like T Cells Enhance Tumor Response in Gastroesophageal Cancer

Less Favored Airway Device in Cardiac Arrest Had Higher Success Rate

Court Orders HHS to Restore $12 Million in Funding for AAP Grants

HPV Vaccine Uptake Is Too Low for Herd Immunity